Treatment of recurrences
Recurrences mainly concern the advanced stages, which occur in a majority of patients, despite a first well-conducted treatment.
These recurrences are classified according to the time between their occurrence and the end of chemotherapy, this time often reflecting the "sensitivity" to chemotherapy (platinum salts).
The situation has changed a lot over the past 10 years with a significant increase in therapeutic possibilities.
Chemotherapy, bevacizumab (AVASTIN), PARP inhibitors and surgery can be used depending on the first treatment received, the time without recurrence, the presence of a mutation in one of the BRCA genes, the location of recurrence, side effects of the first treatment, etc.
The choice between these different treatments is complex and depends on Multidisciplinary Consultation Meetings (RCP) trained in this pathology. The right combination of these treatments is a key to improving the overall prognosis of this disease.
Many therapeutic trials also provide access to new molecules (immunotherapy for example) during relapses. The list of open trials and the teams able to offer them is available on the INCa website.